Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

Bavarian Nordic has won US Food and Drug Administration (FDA) approval for its chikungunya vaccine Vimkunya, becoming the second company in the US to market a vaccine for the tropical disease.

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...